Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.30 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Decane SCHEMBL4288830 | 0.90 | TSHR (0.53) | TSHRLMNACA1CA6CA5A | |
| Decane SCHEMBL4288829 | 0.86 | TSHR (0.57) | TSHRLMNACA1CA6CA5A | |
| Pentane SCHEMBL28529129 | 0.85 | TSHR (0.58) | TSHRLMNACA1CA9THRB | |
| Pentane SCHEMBL28529130 | 0.85 | — | — | |
| Pentane SCHEMBL28840509 | 0.81 | TSHR (0.64) | TSHRLMNATHRBALDH1A1TDP1 | |
| Propane SCHEMBL8326138 | 0.81 | — | — | |
| Butylamine SCHEMBL23930820 | 0.78 | DNM1 (0.50) | TSHRLMNACA1CA6CA5A | |
| SCHEMBL8047792 | 0.78 | — | — | |
| SCHEMBL14746519 | 0.76 | — | — | |
| SCHEMBL1637 | 0.76 | CA1 (0.33) | TSHRLMNACA1CA6CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384195-B2 | Difunctional biphenyl compounds, preparation, and uses | ARIANEGROUP SAS (FR) | 2022-07-12 | — | — | US | claimed |
| EP-3749637-B1 | DIFUNCTIONAL BIPHENYL COMPOUNDS, PREPARATION, AND USES | ARIANEGROUP SAS (FR) | 2021-11-10 | — | — | EP | claimed |
| US-20210324046-A1 | SYSTEMS AND METHODS FOR MANUFACTURE OF ENDOTOXIN-FREE HEMOGLOBIN-BASED DRUG SUBSTANCE | GOLD BLAZE, LTD. (SG) | 2021-10-21 | — | — | US | claimed |
| WO-2021072194-A1 | STABILIZED HEMOGLOBIN COMPOSITIONS AND PHARMACEUTICAL FORMULATIONS THEREOF | MEDICAL TECHNOLOGY ASSOCIATES II, INC. (US) | 2021-04-15 | — | — | WO | claimed |
| US-20200399419-A1 | DIFUNCTIONAL BIPHENYL COMPOUNDS, PREPARATION, AND USES | ARIANEGROUP SAS (FR) | 2020-12-24 | — | — | US | claimed |
| EP-3749637-A1 | DIFUNCTIONAL BIPHENYL COMPOUNDS, PREPARATION, AND USES | ArianeGroup SAS (FR) | 2020-12-16 | — | — | EP | claimed |
| WO-2019155169-A1 | DIFUNCTIONAL BIPHENYL COMPOUNDS, PREPARATION, AND USES | ARIANEGROUP SAS (FR) | 2019-08-15 | — | — | WO | claimed |
| US-20120220529-A1 | NITRIC OXIDE-BLOCKED CROSS-LINKED TETRAMERIC HEMOGLOBIN | IKOR, INC. | 2012-08-30 | — | — | US | claimed |
| US-20120046231-A1 | COMPOSITION AND PROCESS FOR SYNTHESIZING POLYMERIZED HUMAN SERUM ALBUMIN FOR APPLICATIONS IN TRANSFUSION MEDICINE | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-02-23 | — | — | US | claimed |
| US-20120028899-A1 | COMPOSITION AND PROCESS FOR SYNTHESIZING TENSE AND RELAXED STATE POLYMERIZED HEMOGLOBIN | NIH - DEITR | 2012-02-02 | — | — | US | claimed |
| US-4931549-A | Process for aryl-quinone and aryl-naphthoquinone diazide sulfonic acids | HOECHST CELANESE CORPORATION (US) | 1990-06-05 | — | — | US | claimed |
| WO-2024103022-A1 | POLYDOPAMINE ENCAPSULATED MATERIALS AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-4358997-A1 | HEMOGLOBIN-BASED OXYGEN CARRIERS AND METHODS OF MAKING AND USING THEREOF | Ohio State Innovation Foundation (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20230330192-A1 | METHODS OF USING POLYMERIZED HUMAN SERUM ALBUMIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-19 | — | — | US | disclosed |
| WO-2023086152-A1 | SYSTEMS AND METHODS FOR THE PRODUCTION OF METHEMOGLOBIN AND ITS DERIVATIVES | OHIO STATE INNOVATION FOUNDATION (US) | 2023-05-19 | — | — | WO | disclosed |
| US-5691453-A | BLOOD SUBSTITUTES | BIOPURE CORPORATION (US) | 1997-11-25 | — | — | US | disclosed |
| US-5691452-A | DEOXYGENATION; WRAPPING IN A FOIL LAMINATE | BIOPURE CORPORATION (US) | 1997-11-25 | — | — | US | disclosed |
| WO-1996040782-A1 | SEPARATION OF HEMOGLOBIN ON HYDROXYAPATITE USING HPLC | BIOPURE CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996029346-A1 | STABLE POLYMERIZED HEMOGLOBIN BLOOD-SUBSTITUTE | BIOPURE CORPORATION (US) | 1996-09-26 | — | — | WO | disclosed |
| EP-0063043-A1 | Cyclized rubber film-forming negative photoresist composition | PHILIP A. HUNT CHEMICAL CORPORATION (US) | 1982-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399419-A1 | DIFUNCTIONAL BIPHENYL COMPOUNDS, PREPARATION, AND USES | ALK, ALKBH3, AHR | TSHR 3337/4885LMNA 2448/4885CA1 4838/4885 |
| US-11384195-B2 | Difunctional biphenyl compounds, preparation, and uses | ALK, ALKBH3, AHR | TSHR 3337/4885LMNA 2448/4885CA1 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.